Boundless Bio is a clinical-stage biopharmaceutical company focused on developing innovative therapies for the treatment of aggressive cancers linked to extrachromosomal DNA (ecDNA). Founded in 2018 and based in La Jolla, California, the company aims to address the significant unmet medical needs of patients with oncogene amplified tumors, which affect over 14% of cancer patients. By targeting ecDNA, a key factor in oncogene amplification, Boundless Bio seeks to provide transformative treatments for previously difficult-to-treat cancers. One of its leading candidates, BBI-355, is an oral, selective inhibitor of checkpoint kinase 1 (CHK1), designed to manage the replication and transcription of ecDNA in cancer cells.
AMP is an AI technology company that modernizes recycling infrastructure through smart sortation solutions. The company focuses on maximizing resource recovery while minimizing labor costs for waste management operations. With numerous deployments globally, AMP aims to transform the economics of recycling.
Saluda Medical is a commercial-stage medical device company focused on developing innovative treatments for chronic neurological conditions, particularly chronic neuropathic pain. The company utilizes a unique closed-loop neuromodulation platform that senses and measures neural responses to stimulation. This technology automatically adjusts the therapy based on real-time neurophysiological feedback, allowing for personalized treatment tailored to each patient's specific needs. By monitoring the patient's neural fingerprint, Saluda Medical’s devices enable the precise delivery of electrical stimulation, ultimately improving the management of chronic back pain and enhancing patient outcomes.
RayzeBio, Inc. is a biotechnology company based in San Diego, California, founded in 2020. It specializes in developing tumor-targeted small molecule medicines that utilize the therapeutic potential of radioisotopes, particularly Actinium-225, an alpha-emitting radioisotope aimed at treating solid tumors. RayzeBio is focused on enhancing cancer treatment outcomes by creating a robust pipeline of radiopharmaceutical candidates targeting validated oncology drug targets. The company's portfolio includes a range of drug candidates at various stages of development, from discovery to late-stage clinical programs, addressing significant market opportunities in the field of cancer therapeutics.
Meati Foods is a Boulder, Colorado-based company specializing in the production and sale of fungi-based meat alternatives. Founded in 2016, the company aims to provide sustainable and nutritious plant-based options that serve as an alternative to traditional meat products. Meati Foods utilizes a proprietary fermentation process to create minimally processed steaks made from natural ingredients, ensuring its offerings are free from common allergens. The company markets its products online, making them accessible to a wide audience seeking vegan food choices that are both healthy and environmentally friendly.
Moving Analytics is a telehealth service provider that specializes in cardiovascular prevention programs. Its first product Movn is an end-to-end, integrated program to deliver remote and virtual cardiac rehab. The platform reduces readmissions and empowers the effective and efficient delivery of quality care to patients based on 30+ years of research in remote disease management from Stanford University.
FalconX, Ltd. is a cryptocurrency brokerage and digital asset trading platform founded in 2018 and based in San Mateo, California. The company specializes in providing trading solutions for blockchain and fintech sectors, focusing on reliable execution for its clients. Utilizing data science and machine learning, FalconX's platform aims to eliminate slippage and hidden fees, enabling efficient access to cryptocurrency markets. It serves hedge funds, proprietary trading firms, and other institutional clients by facilitating mid-to-large size trades with smart routing across various liquidity sources for optimal pricing.
Guild's lifelong learning platform offers classes, programs, and degrees for working adults, with a path for them to move forward in their education and careers. It offers these adults support from start to finish, with their technology platform for discovery, learning, and organizing the experience, and extra support with their tech-enabled student advising model.
Arcadia, Inc. is a technology company focused on providing access to clean energy through its online platform. Founded in 2014 and based in Washington, D.C., the company connects users—ranging from residential homes to businesses—with renewable energy sources, such as wind farms and community solar projects. Its application enables users to manage their accounts, track energy usage, and participate in clean energy initiatives in their area. By democratizing access to energy data from over 125 utilities across the United States, Arcadia empowers consumers to transition away from fossil fuels and supports efforts to address energy inequality. The company also operates a leading community solar program, which contributes significantly to renewable energy generation while promoting economic growth.
Span.IO designs and develops innovative residential energy storage solutions aimed at facilitating the adoption of renewable energy. The company's flagship product includes a smart electrical panel that replaces traditional panels, providing an intuitive interface for managing home energy use. This system allows users to monitor and control energy consumption remotely through a dedicated application, enhancing the overall consumer experience. Span.IO's team, composed of experts in energy, software, hardware, and consumer finance, leverages their collective knowledge in power generation and system integration to create products that promote environmental sustainability and energy efficiency. Through its technology, Span.IO aims to transform the energy sector by making home energy management more accessible and automated.
Omada Health, Inc. is a digital healthcare company that creates and implements online programs aimed at managing chronic conditions. Founded in 2011 and headquartered in San Francisco, with an additional office in Atlanta, Omada Health focuses on helping employers and health plans identify individuals at risk for preventable chronic diseases such as prediabetes, diabetes, hypertension, and heart disease. The company offers personalized programs that adapt to the unique needs of participants, incorporating professional health coaching, connected health devices, and real-time data to foster sustainable lifestyle changes. Omada Health is recognized as the largest provider of the National Diabetes Prevention Program, delivering clinically effective solutions that empower individuals to take charge of their health and achieve their wellness goals.
Somatus, Inc. is a healthcare company based in McLean, Virginia, specializing in kidney care services. Founded in 2016, it partners with health plans, health systems, nephrology, and primary care groups to offer integrated care for patients with or at risk of developing kidney disease. The company provides a range of services, including home hemodialysis, peritoneal dialysis, in-center hemodialysis, kidney transplantation, and conservative care. Somatus focuses on delaying or preventing the progression of chronic kidney disease and aims to enhance the quality of care through improved coordination and increased utilization of home dialysis and transplantation options. Its approach combines vertically integrated clinical services and technology to optimize patient outcomes.
Synthego Corporation is a genome engineering company focused on advancing life science research and therapeutic development to improve human health. Founded in 2012 and headquartered in Redwood City, California, Synthego offers a comprehensive platform that integrates proprietary hardware, software, bioinformatics, chemistries, and molecular biology. The company's product portfolio includes engineered cells, CRISPR kits, and bioinformatics tools designed for various applications such as pathway analysis, target validation, disease modeling, and diagnostics. By leveraging machine learning and automation, Synthego enables researchers in biotechnology and academia to conduct efficient and precise gene editing, facilitating rapid advancements in drug discovery and development. The company serves a global customer base, distributing its products through various channels, including online sales and partnerships in multiple countries.
CodeSee is a company based in San Francisco, California, that specializes in cloud-based data visualization software aimed at enhancing code comprehension. Founded in 2019, CodeSee's platform provides developers and development teams with tools to continuously grasp their codebase throughout the development process. By mapping the relationships between code and functionality, the software facilitates better understanding and management of complex code structures, ultimately aiding in more efficient software development.
Dave Inc. is a financial services company that operates a mobile application designed to enhance users' financial well-being. Founded in 2015 and based in Los Angeles, California, the app alerts users to potential overdrafts, helps predict expenses, and provides access to up to $250 in overdraft protection. Additionally, it offers features such as credit building and resources for finding side jobs, enabling users to manage their finances more effectively. With a user base exceeding 12 million, Dave aims to provide banking services without hidden fees, acting as a supportive tool for individuals seeking to budget, access funds, and receive financial guidance. The application is available on both the App Store and Google Play.
Rokt is a software development company that specializes in e-commerce technology designed to enhance the consumer purchasing experience by integrating marketing into the transaction moment. By connecting advertisers with customers, Rokt embeds native advertisements into the transaction flows of e-commerce sites, allowing businesses to engage consumers when they are most receptive to promotional messages or upsell opportunities. This approach aims to improve revenue for e-commerce operators while also delivering a more effective customer experience and fostering greater social engagement and cross-selling potential.
Anchorage Digital is a regulated crypto platform that caters to institutional clients by offering integrated financial services and infrastructure solutions. As the only federally chartered crypto bank in the United States, along with its counterpart in Singapore, the company ensures a high standard of security and regulatory compliance. Founded in 2017 and headquartered in San Francisco, Anchorage Digital provides a comprehensive suite of services, including secure custody, trading, staking, and governance, all designed to facilitate safe participation in digital assets. The company has garnered significant investment from leading firms and is valued at over $3 billion. With offices located in New York, Porto, Singapore, and Sioux Falls, Anchorage Digital emphasizes modern security engineering and usability to help businesses streamline their investments through blockchain technology.
Course Hero, Inc. operates an online learning platform that provides students and educators with access to a wide range of study materials. Founded in 2006 and based in Redwood City, California, the platform offers an extensive database of student-uploaded resources, including lecture notes, study guides, textbook solutions, practice problems, exams, and video lectures from various institutions. Additionally, Course Hero features an educator platform for sharing materials and collaborating, along with a flashcard application that enables users to search for existing sets or create their own. The company also connects students with expert tutors who respond to academic queries, fostering a comprehensive learning environment.
Chroma Medicine is a genomic medicine company based in Cambridge, Massachusetts, founded in 2021. The company focuses on epigenetic editing, aiming to revolutionize the treatment of genetically driven diseases. By utilizing epigenetics, which is nature's inherent mechanism for regulating genes, Chroma Medicine develops programmable epigenetic editors that target specific genes and control chromatin conformation. This innovative approach combines a DNA binding domain with epigenetic effector domains, providing medical practitioners with a new class of therapeutics that offers enhanced control over gene expression.
Faire is an online wholesale marketplace that connects retailers with unique merchandise from various brands and makers, facilitating a streamlined purchasing process. The platform provides retailers with tools and insights to manage inventory effectively, employing artificial intelligence and predictive analytics to forecast product demand. Faire's offerings include net 60 payment terms and free returns, which reduce the risks associated with wholesale purchasing, enabling local retailers and independent brands to compete with larger e-commerce entities. Headquartered in San Francisco and Kitchener, Faire aims to support the future of local retail by simplifying logistics and enhancing access to diverse products.
BetterUp Inc. is a leadership development company based in San Francisco that offers a comprehensive online platform for personal and professional growth. Founded in 2013, BetterUp specializes in virtual coaching, providing users with personalized development through one-on-one sessions with a diverse network of over 3,000 coaches across 90 countries. The platform focuses on enhancing mental fitness, career advancement, and social connections, enabling individuals to adopt new behaviors and mindsets for improved performance in a rapidly changing work environment. BetterUp is trusted by more than 380 organizations, including notable companies like NASA and Google, and is recognized as a leader in mental health and coaching. The company’s Science Board includes prominent researchers in positive psychology, further emphasizing its commitment to evidence-based practices. BetterUp has received accolades from various platforms, highlighting its impact and innovation in the field of human transformation.
Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company based in Encinitas, California, that specializes in developing selective inhibitors of TYK2 for autoimmune diseases. Founded in 2018, the company focuses on creating innovative therapies for patients suffering from inflammatory diseases and autoimmune disorders. Its pipeline includes VTX958, an oral allosteric TYK2 inhibitor currently in Phase 1 trials, aimed at treating a variety of autoimmune conditions while minimizing the toxicities associated with broader Janus kinase inhibition. Additionally, Ventyx is advancing VTX002, a Phase 2-ready S1P1 receptor modulator for ulcerative colitis, and VTX2735, a Phase 1 peripheral inhibitor of the NLRP3 inflammasome, which is implicated in several inflammatory conditions. Through these efforts, Ventyx aims to provide effective treatment options for millions of patients.
Archaea Energy, LLC is a developer and producer of renewable natural gas (RNG) based in Belle Vernon, Pennsylvania. Founded in 2018, the company focuses on capturing waste emissions and transforming them into low-carbon fuel, providing a sustainable solution for high-carbon emission processes that are difficult to electrify. Archaea Energy operates an RNG platform that encompasses the development, construction, and maintenance of RNG facilities across the United States. Through its efforts, the company aims to contribute to decarbonization and the transition to cleaner energy sources.
Arcadia, Inc. is a technology company focused on providing access to clean energy through its online platform. Founded in 2014 and based in Washington, D.C., the company connects users—ranging from residential homes to businesses—with renewable energy sources, such as wind farms and community solar projects. Its application enables users to manage their accounts, track energy usage, and participate in clean energy initiatives in their area. By democratizing access to energy data from over 125 utilities across the United States, Arcadia empowers consumers to transition away from fossil fuels and supports efforts to address energy inequality. The company also operates a leading community solar program, which contributes significantly to renewable energy generation while promoting economic growth.
SpotOn is a company dedicated to empowering small and midsize businesses by providing innovative software and payment solutions, complemented by personalized local service. Founded in 2017 and headquartered in San Francisco, SpotOn is recognized for its comprehensive integrated systems designed for the restaurant and retail sectors. Its offerings include point-of-sale solutions, marketing tools, website development, online ordering, appointment scheduling, eCommerce, digital loyalty programs, and review management. The platform is cloud-based, allowing businesses to enhance their operational efficiency and customer engagement through analytics and consistent communication strategies. SpotOn aims to deliver these services at a fair price, positioning itself as a valuable partner for business growth and development.
Asher Biotherapeutics, Inc. is a biotechnology company based in South San Francisco, California, founded in 2019. The company specializes in the development of immunotherapy drugs aimed at effectively treating cancer. Its innovative therapies are designed to enhance the immune system's ability to target and eliminate cancer cells while minimizing side effects. This focus allows healthcare providers to deliver effective treatments to patients in a shorter timeframe, aiming to improve overall outcomes in cancer care.
Trove is a leading company in the branded resale and trade-in industry, primarily based in Ann Arbor, Michigan. The company provides a sophisticated platform that enables brands to efficiently launch, manage, and scale their resale programs, capturing over 75% of the U.S. branded resale market. Trove's platform offers advanced tools for in-store and digital trade-ins, returns processing, and inventory management, which empower brands to connect with diverse customer demographics and optimize their resale strategies through comprehensive analytics. Trove collaborates with notable brands, including Canada Goose, Michael Kors, and Patagonia, enhancing their ability to manage non-new inventory and enabling peer-to-peer sales. As a Certified B Corporation, Trove emphasizes sustainability in retail, aiming to combine commerce with environmental responsibility and drive the industry toward a more sustainable future.
Strata Oncology, Inc. is a precision oncology company focused on improving cancer care by increasing patient access to clinical trials and expediting drug approvals. The company operates a national precision oncology platform that connects patient screening to streamlined enrollment in mutation-matched clinical trials. Strata collaborates with major healthcare systems to facilitate the genomic sequencing of cancer patients' biopsies in high-throughput laboratories, providing oncologists with timely tumor profiles that inform treatment decisions. Its offerings include The Strata Trial, StrataNGS for targeted DNA and RNA sequencing, and StrataPOINT, which integrates electronic medical records with molecular data to ensure comprehensive testing and follow-up for eligible patients. Strata also manages a portfolio of pharmaceutical-sponsored trials tailored to specific biomarkers and operates the Strata Precision Oncology Network, a collaborative effort among cancer centers to advance precision medicine. Founded in 2015 and headquartered in Ann Arbor, Michigan, Strata was previously known as Strata Oncology Research, Inc. until its name change in May 2016.
Thriveworks is a provider of mental health services that focuses on counseling and psychiatric support for individuals facing various life challenges. The company offers a range of services, including therapy for depression and anxiety, marriage counseling, life coaching, and support for relationship issues, low self-esteem, and trauma. Thriveworks emphasizes the importance of personalized care, ensuring that clients receive tailored plans that address their unique mental health needs. Through its diverse offerings, Thriveworks aims to promote overall well-being and assist individuals in navigating their mental health concerns.
Lucid Motors Inc. is an automotive company that specializes in manufacturing electric vehicles. Founded in 2007 and headquartered in Menlo Park, California, the company aims to create cars that enhance the human experience by surpassing traditional limitations of space, performance, and intelligence. Lucid Motors, which was previously known as Atieva, Inc., changed its name in October 2016. The company operates a manufacturing plant in Casa Grande, Arizona, and has established strategic partnerships with battery manufacturers Samsung SDI and LG Chem to support its production efforts.
Sundae operates a residential real estate marketplace designed to assist homeowners in selling their properties off-market. The platform caters particularly to those with dated or damaged homes, allowing sellers to bypass the traditional real estate process, which often involves cleanup, repairs, and showings. By connecting homeowners with a broad network of local investors, Sundae ensures that sellers can achieve a fair price for their properties without the unpredictability commonly associated with real estate transactions. This convenient approach enables individuals to sell their homes on their own timeline, simplifying the selling experience.
HYZON Motors Inc is a manufacturer of hydrogen fuel cell-powered commercial vehicles, including heavy-duty trucks, medium-duty trucks, city buses, and coaches. Founded in 2020 and based in Honeoye Falls, New York, the company operates globally, supplying vehicles across North America, Europe, China, and Australasia. In addition to vehicle manufacturing, HYZON is committed to developing a clean hydrogen supply ecosystem by collaborating with partners involved in feedstock sourcing, production, dispensing, and financing. The company aims to address the growing demand for zero-emission vehicles by utilizing advanced fuel cell and electric propulsion technologies to electrify established vehicle platforms. Future expansion into light-duty commercial vehicles is also anticipated, further broadening its impact in the clean transportation sector.
Markforged is a company that revolutionizes manufacturing through its advanced 3D metal and continuous carbon fiber printers, designed to produce durable parts suitable for industrial environments. Their unified platform, known as the Digital Forge, integrates hardware, software, and materials, streamlining the process from design to functional part production. Markforged's technology is utilized by engineers, designers, and manufacturing professionals across various sectors, including aerospace, automotive, consumer goods, education, electronics, energy, and defense. The company operates globally, with a presence in the Americas, Europe, the Middle East, Africa, and the Asia-Pacific region, making it a key player in the additive manufacturing landscape.
EVgo operates a public fast-charging network for electric vehicles in the United States, providing essential charging infrastructure for both consumers and businesses. Its network features fast chargers that can deliver up to 90 miles of range in just 30 minutes and is compatible with all electric vehicle models that utilize DC fast charging. To expand its reach, EVgo partners with a variety of organizations, including grocery store chains, automotive manufacturers, hotels, shopping centers, gas stations, parking lot operators, local governments, and independent property owners. This collaborative approach allows EVgo to effectively deploy its charging stations in convenient locations, enhancing accessibility for electric vehicle drivers.
Payoneer Inc. is a financial technology company that operates a cross-border payments platform, facilitating transactions for businesses and professionals across various countries and currencies. Founded in 2005 and headquartered in New York, Payoneer offers a range of services, including its Global Payment Service, which allows users to receive local bank transfers from the United States, European Union, and Japan directly into their Payoneer accounts. Additionally, the platform supports mass payouts, enabling Indian companies and marketplaces to transfer funds internationally. Payoneer primarily serves freelancers, e-commerce businesses, and the online advertising sector, and has formed strategic partnerships with various organizations to enhance its service offerings.
Lendbuzz, Inc. operates an innovative car financing platform that utilizes machine learning algorithms to assess the creditworthiness of individuals, particularly those with thin or no credit history. Founded in 2015 and based in Boston, Massachusetts, the company focuses on providing financing solutions for consumers who are often underserved by traditional banks, including international students, foreign professionals, and expatriates. By analyzing a range of background information—such as employment, education, and financial history—Lendbuzz is able to extend loans and refinancing options with favorable terms, regardless of credit score or the presence of a social security number. The platform partners with auto dealerships to facilitate access to financing, allowing consumers to purchase vehicles while enabling dealerships to serve a broader and more diverse client base.
Faire is an online wholesale marketplace that connects retailers with unique merchandise from various brands and makers, facilitating a streamlined purchasing process. The platform provides retailers with tools and insights to manage inventory effectively, employing artificial intelligence and predictive analytics to forecast product demand. Faire's offerings include net 60 payment terms and free returns, which reduce the risks associated with wholesale purchasing, enabling local retailers and independent brands to compete with larger e-commerce entities. Headquartered in San Francisco and Kitchener, Faire aims to support the future of local retail by simplifying logistics and enhancing access to diverse products.
Latch is a company that enhances the living and working experience in buildings through a comprehensive operating system that includes software, devices, and services. Specializing in keyless entry security systems, Latch enables users to manage access to apartment buildings via a smartphone, facilitating seamless interactions for residents, guests, couriers, and service providers. Its platform, LatchOS, is implemented across North America, serving a diverse range of properties from affordable housing in Baltimore to historic buildings in Manhattan and luxury towers in the Midwest. Latch collaborates with a variety of real estate developers, catering to both large international firms and local property owners, to create better living environments.
NiKang Therapeutics is an early-stage biotech company focused on discovering and developing innovative small molecule oncology medicines to help patients with unmet medical needs. Its discovery approach is informed by target structure biology and capitalizes on structure-based drug design enabling a rapid and efficient discovery and development of proprietary drug candidates with the most desirable pharmacological features into clinical studies.
Snapdocs, Inc. is a real estate technology firm based in San Francisco that specializes in creating a digital platform for mortgage closings. Founded in 2013, Snapdocs connects lenders, title companies, and notary signing agents to enhance the efficiency and accuracy of the closing process. The platform automates interactions and workflows, allowing for streamlined operations and improved customer experiences. It offers features that enable lenders to adopt digital closings, providing flexibility in closing types, while also allowing title and escrow clients to automate their workflows. Notary signing agents can showcase their qualifications, and home buyers gain early access to their closing packages, fostering a smoother transaction. By leveraging advanced automation and AI technology, Snapdocs aims to simplify the complexities of mortgage closings, ultimately saving time and reducing costs for all participants involved.
Nuvalent is a clinical-stage biotechnology company focused on developing targeted therapies for cancer, specifically aimed at clinically validated kinase targets. With a strong foundation in structure-based design, Nuvalent creates small molecules that exhibit high selectivity, aiming to address issues of resistance and minimize side effects associated with conventional treatments. The company's pipeline includes lead programs such as NVL-520 for ROS1-positive non-small cell lung cancer (NSCLC) and NVL-655 for ALK-positive NSCLC, as well as several discovery-stage initiatives. All operations are conducted within the United States, where Nuvalent seeks to enhance treatment options for patients with significant unmet medical needs.
Boundless Bio is a clinical-stage biopharmaceutical company focused on developing innovative therapies for the treatment of aggressive cancers linked to extrachromosomal DNA (ecDNA). Founded in 2018 and based in La Jolla, California, the company aims to address the significant unmet medical needs of patients with oncogene amplified tumors, which affect over 14% of cancer patients. By targeting ecDNA, a key factor in oncogene amplification, Boundless Bio seeks to provide transformative treatments for previously difficult-to-treat cancers. One of its leading candidates, BBI-355, is an oral, selective inhibitor of checkpoint kinase 1 (CHK1), designed to manage the replication and transcription of ecDNA in cancer cells.
Current is a consumer fintech banking platform dedicated to enhancing financial access for everyday Americans. The company focuses on developing integrated solutions that address the barriers preventing individuals from achieving their financial goals. With a commitment to simplifying the banking experience, Current aims to empower users to build a more secure financial future. The platform is supported by notable investments from various firms, reflecting its potential impact in the fintech space.
Scale AI, Inc. develops a data platform that specializes in providing training and validation data for artificial intelligence applications. Founded in 2016 and based in San Francisco, the company offers various annotation platforms, including Scale 3D Sensor Fusion for 3D sensor data, Scale Image for images, Scale Video for videos, Scale Text for text annotation, and Scale Document for intelligent document processing. These products facilitate a range of tasks such as content moderation, transcription, and data comparison across multiple sectors, including autonomous vehicles, e-commerce, conversational AI, and robotics. By enabling companies to focus on building advanced AI models rather than labeling data, Scale AI supports clients in accelerating the development of their artificial intelligence applications.
Patreon Inc. is a membership platform founded in 2013 and based in San Francisco, California, that enables artists and content creators to monetize their work through direct relationships with their fans. The platform allows patrons to support creators on a recurring basis in exchange for exclusive benefits and insights into the creative process. By facilitating connections between creators and their audiences, Patreon empowers a new generation of artists to earn a living from their passions. The platform hosts a wide variety of content, including videos, photographs, artwork, audio clips, and other creative materials, fostering a community where fans can actively participate in and support the work they admire.
Entrada Therapeutics, Inc. is a biotechnology company focused on treating diseases through the intracellular delivery of biologics, such as proteins, peptides, and nucleic acids. Founded in 2016 and based in Boston, Massachusetts, the company aims to transform patient care by developing a new class of medicines that target intracellular mechanisms previously deemed inaccessible. Entrada's technology addresses challenges associated with delivering both large and small molecules, significantly enhancing the efficiency of therapeutic delivery into the cytosol. Its pipeline includes innovative therapies for neuromuscular diseases and other conditions, utilizing proprietary Endosomal Escape Vehicle (EEV) therapeutics to improve treatment outcomes across various organs and tissues.
Scribe Therapeutics Inc. is a biotechnology company focused on developing innovative therapeutics based on CRISPR technology to address genetic disorders. Founded in 2017 and headquartered in Berkeley, California, the company utilizes its proprietary X-Editing (XE) platform, which features highly engineered CRISPR enzymes designed to improve the efficacy, specificity, and deliverability of genome editing. Scribe Therapeutics aims to overcome existing limitations in genetic medicine by creating custom-engineered enzymes and advanced delivery systems. Their approach seeks to establish CRISPR-based therapies as a new standard in clinical care, potentially transforming the treatment landscape for various conditions, including immuno-oncology, degenerative disorders, and enzyme replacement therapy. By prioritizing therapeutic precision and allele-specific targeting, Scribe Therapeutics is committed to expanding access to groundbreaking treatments that can significantly impact patient lives.
Cityblock Health is a technology-driven provider focused on meeting the complex health and social needs of Medicaid and Medicare populations. The company delivers a personalized health system that integrates primary care, behavioral health, and social services, partnering with community-based organizations to ensure tailored support for each member. By investing in prevention-oriented care and utilizing technology to enhance coordination and communication, Cityblock aims to improve health outcomes while reducing costs. During the COVID-19 pandemic, the organization developed a model to identify members at high risk, demonstrating its commitment to addressing urgent health challenges within communities.
Arrival Limited is a technology company focused on manufacturing electric vehicles and developing related software, materials, and components. Founded in 2015 and headquartered in London, the company aims to provide zero-emission solutions for urban mobility through innovative, human-centered designs. Arrival also utilizes scalable skateboard platforms and micro-factories, which can be deployed globally to adapt to local mobility ecosystems. This approach allows for cost-effective production with low capital expenditure, enabling the company to address the growing demand for sustainable public transportation options. In addition to its London headquarters, Arrival has offices in several countries, including Germany, the Netherlands, Israel, Russia, and the United States.
Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company based in Encinitas, California, that specializes in developing selective inhibitors of TYK2 for autoimmune diseases. Founded in 2018, the company focuses on creating innovative therapies for patients suffering from inflammatory diseases and autoimmune disorders. Its pipeline includes VTX958, an oral allosteric TYK2 inhibitor currently in Phase 1 trials, aimed at treating a variety of autoimmune conditions while minimizing the toxicities associated with broader Janus kinase inhibition. Additionally, Ventyx is advancing VTX002, a Phase 2-ready S1P1 receptor modulator for ulcerative colitis, and VTX2735, a Phase 1 peripheral inhibitor of the NLRP3 inflammasome, which is implicated in several inflammatory conditions. Through these efforts, Ventyx aims to provide effective treatment options for millions of patients.
Artiva Biotherapeutics is a biotech company focused on developing and manufacturing cellular immunotherapies for cancer patients. Founded in 2019 and based in San Diego, California, Artiva specializes in off-the-shelf, allogeneic natural killer (NK) cell therapies aimed at treating various hematologic cancers and solid tumors. The company's product pipeline targets specific antigens, including CD20 and CD19 for B-cell lymphomas, as well as HER2 for certain solid tumors. Artiva's approach emphasizes the therapeutic potential of NK cells and aims to overcome challenges in scaling and manufacturing these therapies. The company is committed to delivering safe, effective, and readily accessible cell therapies to benefit cancer patients. Artiva operates as a subsidiary of Green Cross Holdings Corporation.
Centessa Pharmaceuticals is a next-generation biopharmaceutical company that aims to reshape the traditional drug development process. The company applies an asset-centric R&D model at scale to advance a portfolio of highly validated programs led by industry-leading teams. Each program is developed by a Centessa Subsidiary and supported by a centralized infrastructure and the Centessa management team.
Butterfly Network develops innovative medical imaging devices designed to enhance point-of-care ultrasound programs in hospitals and healthcare organizations. Founded in 2011 and based in Guilford, Connecticut, the company has created the first handheld, single-probe whole-body ultrasound system, utilizing its patented Ultrasound-on-Chip technology. This compact device enables healthcare professionals to perform diagnostic imaging across various medical fields, including cardiology, urology, and obstetrics, all while integrating seamlessly into clinical workflows through mobile applications. Butterfly Network aims to democratize access to medical imaging, particularly for the 4.7 billion individuals globally who currently lack access to ultrasound, thereby promoting early detection and remote management of health conditions.
Gemini Therapeutics, Inc. is a precision medicine company based in Cambridge, Massachusetts, established in 2015. The company is dedicated to developing innovative therapies for patients with dry age-related macular degeneration (AMD) and related rare genetic diseases. Gemini Therapeutics focuses on genetically defined conditions, ensuring that their therapeutic candidates are tailored to the specific molecular abnormalities found in patients with significant clinical needs. Their extensive pipeline includes a range of modalities such as monoclonal antibodies, recombinant proteins, and gene therapies. Supported by prominent life science investors and global academic collaborations, Gemini Therapeutics aims to create potentially first-in-class therapeutics to address unmet medical needs in the field of ophthalmology.
Design Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative therapies for degenerative disorders linked to nucleotide repeat expansions. Founded in 2017 and headquartered in Solana Beach, California, the company is advancing its lead program aimed at treating Friedreich’s ataxia. Additionally, Design Therapeutics is exploring treatments for other conditions such as Fragile X syndrome and myotonic dystrophy, utilizing its proprietary GeneTACTM technology, which involves small-molecule gene-targeted therapeutics designed to modify the underlying causes of these inherited diseases. The company is committed to addressing serious monogenic disorders driven by nucleotide repeat mutations through its ongoing research and development efforts.
Verve Therapeutics, Inc. is a genetic medicines company focused on innovative treatments for cardiovascular disease through gene editing. Founded in 2018 and based in Cambridge, Massachusetts, with a research facility in Philadelphia, the company aims to shift the management of cardiovascular conditions from chronic treatments to single-course gene editing therapies. Its initial programs concentrate on the PCSK9 and ANGPTL3 genes, which are known to significantly impact blood lipid levels, a major factor in cardiovascular disease. Verve Therapeutics collaborates with partners such as Beam Therapeutics and Verily to enhance its gene editing delivery technologies. The company is staffed by a team of experts in cardiovascular medicine, human genetics, and drug development, positioning itself to address the challenges of cardiovascular health effectively.
Billtrust is a provider of cloud-based software and integrated payment processing solutions designed to enhance B2B commerce by automating accounts receivable (AR) processes. Recognizing the inefficiencies of traditional, paper-based methods, Billtrust aims to digitally transform AR through a comprehensive platform that covers the entire order-to-cash cycle. This includes key functions such as credit decisioning, online ordering, invoicing, cash application, and collections. By integrating with various ecosystem participants, including financial institutions and enterprise resource planning systems, Billtrust enables businesses to transition from costly paper invoicing to efficient electronic billing and payments. This transformation accelerates revenue capture, improves cash flow, and enhances the overall user experience for clients.
Affinivax, Inc. is a biotechnology company based in Lexington, Massachusetts, focused on developing innovative vaccines using its proprietary Multiple Antigen Presenting System (MAPS) technology. This approach allows for the combination of protective polysaccharides and proteins into a single vaccine, thereby enhancing immune responses against a variety of infectious diseases affecting both children and adults. Affinivax targets several significant pathogens, including Streptococcus pneumoniae, bacterial nosocomial infections, Salmonella typhi, and Staphylococcus aureus. The company aims to create vaccines that not only provide broader disease coverage compared to existing options but also address infectious diseases lacking effective immunization strategies. Founded in 2014, Affinivax benefits from the expertise of leading professionals in infectious diseases and vaccines, and it has received backing from the Bill & Melinda Gates Foundation, along with an exclusive license from Boston Children’s Hospital for its MAPS technology.
Scorpion Therapeutics, Inc. is a biotechnology company based in Boston, Massachusetts, focused on developing next-generation precision oncology technologies for cancer treatment. Founded in 2020, the company specializes in creating targeted small-molecule drugs that interact with validated cancer targets. Its research encompasses therapies aimed at known oncogenes, previously undruggable cancer targets, and novel targets. By integrating technologies across target discovery, medicinal chemistry, and translational medicine, Scorpion Therapeutics aims to advance a comprehensive pipeline of optimized compounds. The company's goal is to expand the reach of precision medicine, enabling healthcare professionals to offer innovative treatments to a broader range of cancer patients.
Porch.com, Inc. operates an online platform that connects homeowners with local home repair services and facilitates the arrangement of set-up and installation for purchased goods. The company offers a service called Service Attach, which allows customers to add installation or assembly services to their online shopping carts. Additionally, Porch provides a moving concierge service to homebuyers, assisting them in making informed decisions about essential services such as insurance, security, and home improvement. Porch Group is structured into two main segments: the vertical software segment, which supplies software and services to home service companies, and an insurance segment that offers consumers various protection products for their homes. Established in 2011 and based in Seattle, Washington, Porch has formed a strategic partnership with Cinch Home Services Inc. to enhance its offerings.
Cityblock Health is a technology-driven provider focused on meeting the complex health and social needs of Medicaid and Medicare populations. The company delivers a personalized health system that integrates primary care, behavioral health, and social services, partnering with community-based organizations to ensure tailored support for each member. By investing in prevention-oriented care and utilizing technology to enhance coordination and communication, Cityblock aims to improve health outcomes while reducing costs. During the COVID-19 pandemic, the organization developed a model to identify members at high risk, demonstrating its commitment to addressing urgent health challenges within communities.
Edgewise Therapeutics is a clinical-stage biopharmaceutical company based in Boulder, Colorado, that specializes in developing small molecule therapies for severe, rare musculoskeletal diseases. Founded in 2017, the company employs a precision medicine approach to create innovative treatments targeting various muscle disorders, including Duchenne and Becker muscular dystrophies, as well as limb girdle muscular dystrophies. Utilizing its proprietary muscle-focused drug discovery platform, Edgewise integrates expertise in muscle biology and small molecule engineering to identify and develop therapies that address genetically defined muscle disorders. The company emphasizes a holistic drug discovery method that assesses integrated muscle function, enabling it to create orally bioavailable therapies aimed at improving outcomes for patients with significant unmet medical needs in neuromuscular and cardiac diseases.
Current is a consumer fintech banking platform dedicated to enhancing financial access for everyday Americans. The company focuses on developing integrated solutions that address the barriers preventing individuals from achieving their financial goals. With a commitment to simplifying the banking experience, Current aims to empower users to build a more secure financial future. The platform is supported by notable investments from various firms, reflecting its potential impact in the fintech space.
Scopely, Inc. is an interactive entertainment and video game company that develops mobile and tablet games for casual and core gamers globally. Founded in 2011 and headquartered in Culver City, California, Scopely is known for its award-winning franchises such as "Star Trek™ Fleet Command," "MARVEL Strike Force," "Stumble Guys," and "Yahtzee With Buddies." The company specializes in creating, publishing, and live-operating immersive gaming experiences, supported by its proprietary technology platform, Playgami™. Scopely's diverse portfolio and commitment to consumer-driven gaming have positioned it as a significant player in the mobile gaming industry, with operations in numerous global markets, including Asia-Pacific, EMEA, and North America. Its broad range of services encompasses game design, live operations, marketing, and analytics, enhancing the overall gaming experience for users.
Lordstown Motors is an automotive company focused on developing and manufacturing light-duty electric trucks, primarily aimed at fleet customers. The company's engineering, research, and development facilities are located in Farmington Hills, Michigan, and Irvine, California. Its flagship vehicle, the Endurance all-electric pickup truck, is being produced at the company's facility in Lordstown, Ohio. Currently, Lordstown Motors is in the final design and testing phase for the Endurance, with plans to bring the completed product to market soon.
Nuvation Bio Inc. is a biopharmaceutical company dedicated to developing innovative therapies for oncology, addressing unmet medical needs in the treatment of challenging cancers that have not responded to conventional therapies. Founded in 2018 and based in New York, with an additional office in San Francisco, the company has a portfolio of drug development candidates aimed at improving patient outcomes. One of its key clinical-stage candidates is NUV-868, an oral small molecule BET inhibitor that targets the BRD4 protein, which plays a crucial role in regulating tumor growth and differentiation. Additionally, Nuvation Bio is advancing its proprietary small molecule Drug-Drug Conjugate platform, further expanding its therapeutic arsenal in oncology.
Olema Oncology is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for estrogen receptor (ER) positive breast cancer. The company specializes in the discovery and commercialization of targeted treatments aimed at improving outcomes for women with cancer. Olema utilizes its extensive knowledge of endocrine-driven cancers and the molecular mechanisms of the ER to create drug candidates that are designed to outperform existing therapies. Currently, the company's product pipeline includes OP-1250 and OP-3136, both of which have completed discovery and preclinical studies. Olema's mission is to transform the standard of care for both pre- and post-menopausal women by providing more effective and convenient treatment options.
Novellus is a biotechnology company working to develop engineered cellular medicines. The company uses its non-immunogenic mRNA molecules to reprogram and gene-edit cells safely, and with high efficiency. They engineer precision medicines for patient segments and select from its technology toolbox for in vivo, ex vivo, allogeneic and autologous delivery. Novellus platform enables the high-level expression of gene-editing and cell-reprogramming proteins for high-specificity gene repair and both autologous and allogeneic cell therapies. The company is advancing its lead program, a breakthrough therapy for a rare dermatologic disease, through pre-clinical studies. Novellus was founded in 2015 and is headquartered in Cambridge, Massachusetts, United States.
Attentive is a leader in conversational commerce, offering a personalized mobile messaging platform that facilitates communication between businesses and consumers. The platform leverages behavioral data to enable brands to send automated, tailored messages throughout the customer lifecycle, including product recommendations, promotions, and real-time customer support. By focusing on SMS communication, Attentive helps entrepreneurs and enterprises engage more effectively with their customers, enhancing relationships and driving sales in the e-commerce and retail sectors.
Affirm is a financial technology company based in San Francisco, California, that specializes in providing installment loans to consumers at the point of sale. Founded in 2012, Affirm offers a platform that allows users to make purchases from online merchants and pay for them in fixed monthly installments. This service provides a transparent alternative to traditional credit cards, as it enables consumers to see upfront what they will pay each month, without hidden fees or unexpected costs. Affirm partners with over 2,000 merchants across various sectors, including retail, travel, and personal fitness, allowing shoppers to select Affirm as a payment option at checkout. The company aims to empower consumers with honest financial products and improve accessibility in the banking industry.
ESCAPE Bio is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies for genetically defined subpopulations affected by neurodegenerative diseases. Founded in 2015 and based in South San Francisco, California, the company aims to improve the lives of patients suffering from conditions such as Alzheimer's disease, Parkinson's disease, and sphingolipid storage disorders. ESCAPE Bio's pipeline includes innovative candidates like ESB1609, a small molecule S1P5 receptor agonist targeting CNS lysosomal storage disorders, and ESB5070, a kinase inhibitor specifically designed for Parkinson's patients with the LRRK2 G2019S variant. Additionally, the company is developing a program aimed at addressing the needs of Alzheimer's patients who carry the ApoE4 risk allele. Through its precision-targeted approach, ESCAPE Bio seeks to provide effective treatment options for individuals with these complex genetic profiles.
Skillz is a mobile gaming platform dedicated to fostering competition through engaging and fair gameplay. By enabling developers to create and monetize competitive games, Skillz has positioned itself as a leader in the mobile gaming industry. The platform hosts billions of casual gaming tournaments, attracting millions of players globally. Notable games available on Skillz include Dominoes Gold, Blackout Bingo, 21 Blitz, and Solitaire Cube. The company operates primarily through its Skillz segment, which focuses on eSports and multiplayer competition, while also encompassing the Aarki segment. Skillz generates most of its revenue from the United States, with additional contributions from markets such as Israel, China, and Malta. The company has received recognition for its commitment to diversity and innovation in technology, being named among the Best Companies for Women to Advance and one of Fast Company’s Most Innovative Companies.
Patreon Inc. is a membership platform founded in 2013 and based in San Francisco, California, that enables artists and content creators to monetize their work through direct relationships with their fans. The platform allows patrons to support creators on a recurring basis in exchange for exclusive benefits and insights into the creative process. By facilitating connections between creators and their audiences, Patreon empowers a new generation of artists to earn a living from their passions. The platform hosts a wide variety of content, including videos, photographs, artwork, audio clips, and other creative materials, fostering a community where fans can actively participate in and support the work they admire.
Synthego Corporation is a genome engineering company focused on advancing life science research and therapeutic development to improve human health. Founded in 2012 and headquartered in Redwood City, California, Synthego offers a comprehensive platform that integrates proprietary hardware, software, bioinformatics, chemistries, and molecular biology. The company's product portfolio includes engineered cells, CRISPR kits, and bioinformatics tools designed for various applications such as pathway analysis, target validation, disease modeling, and diagnostics. By leveraging machine learning and automation, Synthego enables researchers in biotechnology and academia to conduct efficient and precise gene editing, facilitating rapid advancements in drug discovery and development. The company serves a global customer base, distributing its products through various channels, including online sales and partnerships in multiple countries.
Dyne Therapeutics is a biotechnology company based in Waltham, Massachusetts, dedicated to developing targeted therapies for genetically driven muscle diseases. Founded in 2017, the company focuses on advancing treatments for conditions such as myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral dystrophy, among others. Utilizing its innovative FORCE platform, Dyne Therapeutics aims to deliver disease-modifying therapies with enhanced precision to skeletal, cardiac, and smooth muscle tissues. The company's lead product candidates, DYNE-101 and DYNE-251, are currently undergoing phase 1/2 clinical trials, reflecting its commitment to addressing the unmet medical needs of patients with serious muscle disorders.
PMV Pharmaceuticals, Inc. is a precision oncology company focused on discovering and developing small molecule therapies targeting p53 mutations in cancer. The company's lead candidate, PC14586, aims to correct and restore the function of p53, a critical tumor suppressor protein. In addition to this product, PMV Pharmaceuticals is also working on therapies for specific p53 hotspot mutations, including the R273H mutation. Founded in 2013 and headquartered in Cranbury, New Jersey, the company leverages over three decades of expertise in p53 biology, aiming to develop first-in-class modulators that could improve treatment outcomes for cancer patients.
Olema Oncology is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for estrogen receptor (ER) positive breast cancer. The company specializes in the discovery and commercialization of targeted treatments aimed at improving outcomes for women with cancer. Olema utilizes its extensive knowledge of endocrine-driven cancers and the molecular mechanisms of the ER to create drug candidates that are designed to outperform existing therapies. Currently, the company's product pipeline includes OP-1250 and OP-3136, both of which have completed discovery and preclinical studies. Olema's mission is to transform the standard of care for both pre- and post-menopausal women by providing more effective and convenient treatment options.
VelosBio, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing innovative antibody-drug conjugates (ADCs) to treat various forms of cancer, including hematological cancers and solid tumors. The company's primary area of research centers on targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1), a cell-surface protein found in numerous tumors but absent in normal tissues, which makes it a promising target for cancer therapy. VelosBio's lead product, VLS-101, is a ROR1-directed ADC that has shown positive preclinical results and aims to provide new treatment options for patients. Founded in 2017, VelosBio operates under the umbrella of Merck & Co., Inc. as of December 2020, focusing on developing targeted therapies that can be administered alone or in combination with other treatments across a wide range of cancer types.
Goldfinch Bio, Inc. is a clinical-stage biotechnology company based in Cambridge, Massachusetts, dedicated to discovering and developing precision therapies for patients with kidney diseases. The company focuses on conditions such as focal segmental glomerulosclerosis, diabetic nephropathy, and polycystic kidney disease. Key product candidates include GFB-887, a selective inhibitor of the TRPC5 channel, and GFB-024, a cannabinoid receptor 1 inverse agonist. Goldfinch Bio integrates advancements in kidney genetics and biology through its Kidney Genome Atlas, a genomic registry that aids in identifying new disease targets and biomarkers. Additionally, the company employs stem cell science to create human organoid models, which facilitate the validation of novel therapeutic targets. Goldfinch Bio has established a strategic collaboration with Gilead Sciences to further enhance its research and development efforts. Founded in 2016, Goldfinch Bio aims to transform the treatment landscape for progressive kidney disease.
Prove is a New York-based identity verification startup that focuses on smartphone-based solutions to enhance security and consumer privacy. The company specializes in phone-centric and API marketplace offerings that facilitate customer acquisition and engagement by streamlining processes and minimizing friction. Prove's software is designed to protect against identity theft and social engineering attacks, providing instant mobile authentication that improves the overall customer experience. By leveraging these technologies, Prove enables its clients to enhance security measures while reducing the risk of fraud. Its solutions are utilized across various sectors, including financial services, healthcare, and retail, to ensure safe and efficient identity verification.
Verve Therapeutics, Inc. is a genetic medicines company focused on innovative treatments for cardiovascular disease through gene editing. Founded in 2018 and based in Cambridge, Massachusetts, with a research facility in Philadelphia, the company aims to shift the management of cardiovascular conditions from chronic treatments to single-course gene editing therapies. Its initial programs concentrate on the PCSK9 and ANGPTL3 genes, which are known to significantly impact blood lipid levels, a major factor in cardiovascular disease. Verve Therapeutics collaborates with partners such as Beam Therapeutics and Verily to enhance its gene editing delivery technologies. The company is staffed by a team of experts in cardiovascular medicine, human genetics, and drug development, positioning itself to address the challenges of cardiovascular health effectively.
Nurix Therapeutics is a biopharmaceutical company specializing in the discovery, development, and commercialization of small molecule therapies aimed at modulating cellular protein levels to treat cancer and immune disorders. The company's pipeline includes promising preclinical candidates such as NX-2127, an orally available Bruton’s tyrosine kinase degrader targeted at relapsed or refractory B-cell malignancies, and NX-1607, a Casitas B-lineage lymphoma proto-oncogene-B inhibitor for immuno-oncology applications. Nurix's innovative drug discovery platform, DELigase, leverages its expertise in E3 ligases—enzymes that regulate protein modulation within cells—to identify and advance novel drug candidates. Founded in 2009 and based in San Francisco, Nurix Therapeutics aims to provide effective therapies for challenging diseases through its cutting-edge research and development efforts.
Kymera Therapeutics is a biopharmaceutical company based in Watertown, Massachusetts, that specializes in the discovery and development of novel small molecule therapeutics aimed at selectively degrading disease-causing proteins. The company utilizes a proprietary platform for targeted protein degradation, leveraging the body’s natural protein recycling system. Kymera is developing several programs, including the IRAK4 program for immunology-inflammation diseases such as hidradenitis suppurativa and rheumatoid arthritis, the IRAKIMiD program to address MYD88-mutated diffuse large B cell lymphoma, and the STAT3 program targeting hematologic malignancies, solid tumors, and autoimmune diseases. Founded in 2015, Kymera Therapeutics is pioneering new approaches to treat diseases that have previously been considered untreatable, focusing on previously inaccessible therapeutic targets.
Generation Bio is a genetic medicines company based in Cambridge, Massachusetts, that specializes in developing innovative gene therapies for both rare and prevalent diseases. Founded in 2016 and originally named Torus Therapeutics, the company focuses on treating conditions primarily affecting the liver and retina, as well as diseases of skeletal muscle, the central nervous system, and oncology. Generation Bio employs a proprietary non-viral platform that includes a high-capacity DNA construct known as closed-ended DNA (ceDNA) and a cell-targeted lipid nanoparticle delivery system (ctLNP). This platform aims to deliver genetic payloads effectively across various tissues and allows for redosable treatments tailored to individual patient needs. Through its advanced manufacturing processes, Generation Bio seeks to expand access to gene therapies and provide durable solutions for patients with both rare and common diseases.
Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of viral infections and liver diseases. Aligos is focused on the development of targeted antiviral therapies for chronic hepatitis B (CHB) and coronaviruses as well as leveraging its expertise in liver diseases to create targeted therapeutics for nonalcoholic steatohepatitis (NASH). Aligos’ strategy is to harness the deep expertise and decades of drug development experience its workforce has in liver disease, particularly viral hepatitis, to rapidly advance its pipeline of potentially best-in-class molecules.
FORMA Therapeutics is a clinical-stage biopharmaceutical company based in Watertown, Massachusetts, specializing in the development and commercialization of innovative therapeutics for rare hematologic diseases and various cancers. The company's notable product candidates include FT-4202, currently in Phase 1 trials for sickle cell disease and other hemoglobinopathies, and FT-7051, which targets metastatic castration-resistant prostate cancer. Additionally, FORMA is advancing FT-2102, an oral investigational agent designed to inhibit mutated IDH1 enzymes, now being evaluated in Phase 2 trials for relapsed/refractory acute myeloid leukemia and exploratory Phase 1 trials for glioma. The company also develops FT-4101 and FT-8225, selective inhibitors of fatty acid synthase. By integrating advanced drug discovery technologies and oncology expertise, FORMA aims to target challenging biological pathways that contribute to cancer, thereby enhancing the development of small molecule drug candidates with unique mechanisms of action.
Black Diamond Therapeutics is a precision oncology medicine company focused on discovering and developing small molecule therapies that are tumor-agnostic. The company’s lead product candidate, BDTX-189, targets non-canonical and oncogenic mutations in ErbB kinases, specifically the epidermal growth factor receptor and tyrosine-protein kinase. In addition to BDTX-189, Black Diamond is developing allosteric-EGFR mutation inhibitors and other early-stage pipeline programs that address allosteric mutations in kinases associated with cancer and rare genetic diseases. The company's approach is centered on its Mutation-Allostery-Pharmacology platform, which aims to create targeted treatments for genetically defined cancers, especially for patients with limited existing treatment options. Founded in 2014 and headquartered in Cambridge, Massachusetts, Black Diamond Therapeutics was previously known as ASET Therapeutics until its name change in January 2018.
Impulse Dynamics N.V. is a medical device company focused on developing electrical therapies for chronic heart failure, operating primarily in the United States and Europe. The company's key innovation is its cardiac contractility modulation (CCM) therapy, which utilizes non-excitatory electrical impulses delivered to the heart muscles. This therapy aims to enhance cardiac strength and improve blood flow, offering a minimally invasive treatment option for patients with limited alternatives. Impulse Dynamics conducts clinical trials to assess the safety and efficacy of its therapies and collaborates with universities and hospitals for research initiatives. Founded in 1996 and headquartered in Willemstad, Curacao, the company also maintains offices in New York and Hong Kong, alongside product development centers in New Jersey and Israel.
ACV Auctions, Inc. is a wholesale automotive auction company headquartered in Buffalo, New York, founded in 2014. It operates a mobile platform that facilitates online auctions for used-car dealers, allowing them to view, bid on, and purchase car inventory directly from other dealers. The platform provides a digital marketplace that streamlines the buying and selling process, offering real-time alerts for available vehicles and enabling live auction participation. Additionally, ACV Auctions offers a pricing application tailored for franchise dealers, enhancing the auction experience and providing transparent and accurate vehicle information to users.
Current is a consumer fintech banking platform dedicated to enhancing financial access for everyday Americans. The company focuses on developing integrated solutions that address the barriers preventing individuals from achieving their financial goals. With a commitment to simplifying the banking experience, Current aims to empower users to build a more secure financial future. The platform is supported by notable investments from various firms, reflecting its potential impact in the fintech space.
Omada Health, Inc. is a digital healthcare company that creates and implements online programs aimed at managing chronic conditions. Founded in 2011 and headquartered in San Francisco, with an additional office in Atlanta, Omada Health focuses on helping employers and health plans identify individuals at risk for preventable chronic diseases such as prediabetes, diabetes, hypertension, and heart disease. The company offers personalized programs that adapt to the unique needs of participants, incorporating professional health coaching, connected health devices, and real-time data to foster sustainable lifestyle changes. Omada Health is recognized as the largest provider of the National Diabetes Prevention Program, delivering clinically effective solutions that empower individuals to take charge of their health and achieve their wellness goals.
Away is a modern travel and lifestyle brand. The company is a vertically-integrated company offering beautiful, high-quality luggage at an affordable price point. Away designs special objects for modern travel. It started with luggage, designed with thoughtful features that solve real travel problems—for life. Now all that’s left is the world in front of you and the people you share it with. Because getting Away means getting more out of every trip to come.
Satsuma Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing innovative treatments for migraine. The company's lead product candidate, STS101, is a drug-device combination that features a proprietary dry-powder formulation of dihydroergotamine mesylate. This product is designed for self-administration through a pre-filled, single-use nasal delivery device and is currently undergoing Phase III clinical trials. Founded in 2016 and based in South San Francisco, California, Satsuma aims to provide an effective therapeutic option for individuals suffering from acute migraine episodes.
Prove is a New York-based identity verification startup that focuses on smartphone-based solutions to enhance security and consumer privacy. The company specializes in phone-centric and API marketplace offerings that facilitate customer acquisition and engagement by streamlining processes and minimizing friction. Prove's software is designed to protect against identity theft and social engineering attacks, providing instant mobile authentication that improves the overall customer experience. By leveraging these technologies, Prove enables its clients to enhance security measures while reducing the risk of fraud. Its solutions are utilized across various sectors, including financial services, healthcare, and retail, to ensure safe and efficient identity verification.
Affirm is a financial technology company based in San Francisco, California, that specializes in providing installment loans to consumers at the point of sale. Founded in 2012, Affirm offers a platform that allows users to make purchases from online merchants and pay for them in fixed monthly installments. This service provides a transparent alternative to traditional credit cards, as it enables consumers to see upfront what they will pay each month, without hidden fees or unexpected costs. Affirm partners with over 2,000 merchants across various sectors, including retail, travel, and personal fitness, allowing shoppers to select Affirm as a payment option at checkout. The company aims to empower consumers with honest financial products and improve accessibility in the banking industry.
ezCater, Inc. is an online catering marketplace that facilitates food ordering for both small businesses and large corporations, including Fortune 500 companies. Founded in 2007 and headquartered in Boston, Massachusetts, with an additional office in Denver, Colorado, ezCater connects users to a nationwide network of local caterers and restaurants. The platform allows clients to efficiently search for caterers based on specific criteria such as food type and budget, streamlining the process of ordering food for meetings and events. ezCater also offers ezManage, a catering management tool, and ezOrdering, which enables restaurants to accept online catering orders directly through their own websites.
Auris Health, Inc., based in Redwood City, California, develops innovative robotic technology for medical applications, particularly in the field of endoscopy. The company is known for its Monarch Platform, which facilitates diagnostic and therapeutic bronchoscopic procedures by utilizing small cameras and tools that access the body through natural openings. In addition to endoscopic applications, Auris Health is creating a novel dual-arm microsurgical system aimed at enhancing ophthalmic surgery. By integrating advancements in imaging technology, robotics, micro-instrumentation, and data science, Auris Health seeks to transform medical interventions, ultimately improving patient outcomes and reducing costs. Founded in 2007, the company operates as a subsidiary of Johnson & Johnson.
Coinbase, Inc. operates a digital platform that enables merchants, consumers, and traders to buy, sell, and store various cryptocurrencies, including bitcoin, Ethereum, and Litecoin. Founded in 2012 and based in San Francisco, the company offers a range of services such as Coinbase.com for transactions, a digital wallet for users, and merchant tools to facilitate payment processing on popular websites. Additionally, Coinbase Ventures, established in 2018, serves as the company's investment arm, focusing on early-stage startups in the cryptocurrency and blockchain sectors. Through its various offerings, Coinbase aims to create an open financial system, making digital currency accessible and usable for a broad audience.
Private Equity Round in 2018
Tanium Inc. is a provider of security and management system solutions that enable enterprises and government organizations to effectively query and manage their computer assets. The company offers a range of products, including the Tanium Endpoint Platform, which secures and manages endpoints; Tanium Asset for inventory tracking; Tanium Deploy for managing software installations and updates; and Tanium Patch for operating system and application patch management. Tanium’s platform facilitates real-time data collection, allowing organizations to gain visibility into their endpoints and respond swiftly to security threats and incidents. The solutions help reduce management costs, reclaim software licenses, and optimize operational efficiency. Founded in 2007 and headquartered in Kirkland, Washington, Tanium serves various industries, including banking and retail, and maintains strategic partnerships with companies such as PwC and Palo Alto Networks. The company also has offices in several international locations, including the United Kingdom, Germany, France, Japan, and Australia.